Citations

Showing 10 of 108119 citations.

Patient-oriented education and visual-aid intervention are inadequate to identify patients with potential capsule retention: a prospective randomized study
Al‐Bawardy, Badr , Kamboj, Amrit K. , Desai, Shiv, Gorospe, Emmanuel C., Bruining, David H. , Gostout, Christopher J., Larson, Mark V., Nehra, Vandana, Leggett, Cadman L. , Szarka, Lawrence A., Watson, Robert E. , Rajan, Elizabeth , Gorospe, Emmanuel, Hansel, Stephanie L. , Leggett, Cadman L , Murray, Joseph A.

Mayo Clinic

Scandinavian Journal of Gastroenterology | April 30, 2019 | Volume: 54 | Issue: 5 | Pages: 662-665

10.1080/00365521.2019.1608465 | PMID 31034255 Get It

Volumetric laser endomicroscopy and its application to Barrett's esophagus: results from a 1,000 patient registry
Smith, Michael S. , Konda, Vani J. , Gordon, Stuart R. , DeMeester, Steven R. , Joshi, Vivek , Ganguly, Eric K. , Mashimo, Hiroshi , Jobe, Blair A. , McKinley, Matthew , Wallace, Michael B. , Thakkar, Shyam , Schnoll‐Sussman, Felice , Sharaiha, Reem Z. , Tarnasky, P, Wolfsen, Herbert C. , Hawes, Robert H. , Lipham, John C. , Khara, Harshit S. , Navaneethan, U, Kedia, Prashant , Hasan, Muhammad K. , Sethi, Amrita , Samarasena, Jason , Siddiqui, Uzma D. , Gress, Frank G., Rodríguez, Reynaldo , Lee, C, Gonda, Tamas A. , Waxman, Irving , Hyder, S., Poneros, John M., Sharzehi, Kaveh , Palma, Jack A. Di, Sejpal, Divyesh V., Hagen, J. A., Rothstein, Richard, Sawhney, Mandeep , Malik, Zubair , Chang, Kenneth J. , Fichera, Alessandro , Gaidhane, Monica , Wallace, Michael B , Cash, Brooks D. , Trindade, Arvind J. , Diehl, David L. , Singh, Satish K. , Komatsu, Y, Kahaleh, Michel , Pleskow, Douglas K. , Hyder, S, Oh, Daniel S. , Berzin, Tyler M.

Mayo Clinic

Diseases of the Esophagus | April 30, 2019 | Volume: 32 | Issue: 9 | Pages: No page available

10.1093/dote/doz029 | PMID 31037293 Get It

SUMMARY Volumetric laser endomicroscopy (VLE) uses optical coherence tomography (OCT) for real-time, microscopic cross-sectional imaging. A US-based multi-center registry was constructed to prospectively collect data on patients undergoing upper endoscopy during which a VLE scan was performed. The objective of this registry was to determine usage patterns of VLE in clinical practice and to estimate quantitative and qualitative performance metrics as they are applied to Barrett's esophagus (BE) management. All procedures utilized the NvisionVLE Imaging System (NinePoint Medical, Bedford, MA) which was used by investigators to identify the tissue types present, along with focal areas of concern. Following the VLE procedure, investigators were asked to answer six key questions regarding how VLE impacted each case. Statistical analyses including neoplasia diagnostic yield improvement using VLE was performed. One thousand patients were enrolled across 18 US trial sites from August 2014 through April 2016. In patients with previously diagnosed or suspected BE (894/1000), investigators used VLE and identified areas of concern not seen on white light endoscopy (WLE) in 59% of the procedures. VLE imaging also guided tissue acquisition and treatment in 71% and 54% of procedures, respectively. VLE as an adjunct modality improved the neoplasia diagnostic yield by 55% beyond the standard of care practice. In patients with no prior history of therapy, and without visual findings from other technologies, VLE-guided tissue acquisition increased neoplasia detection over random biopsies by 700%. Registry investigators reported that VLE improved the BE management process when used as an adjunct tissue acquisition and treatment guidance tool. The ability of VLE to image large segments of the esophagus with microscopic cross-sectional detail may provide additional benefits including higher yield biopsies and more efficient tissue acquisition. Clinicaltrials.gov NCT02215291
Mid-term radiological results of a cementless short humeral component in anatomical and reverse shoulder arthroplasty
Aibinder, William R. , Bartels, D , Sperling, John W. , Aibinder, William R , Sánchez‐Sotelo, Joaquín

Mayo Clinic

The Bone & Joint Journal | April 30, 2019 | Volume: 101-B | Issue: 5 | Pages: 610-614

10.1302/0301-620x.101b5.bjj-2018-1374.r1 | PMID 31039055 Get It

Aims Shoulder arthroplasty using short humeral components is becoming increasingly popular. Some such components have been associated with relatively high rates of adverse radiological findings. The aim of this retrospective review was to evaluate the radiological humeral bone changes and mechanical failure rates with implantation of a short cementless humeral component in anatomical (TSA) and reverse shoulder arthroplasty (RSA). Patients and Methods A total of 100 shoulder arthroplasties (35 TSA and 65 RSA) were evaluated at a mean of 3.8 years (3 to 8.3). The mean age at the time of surgery was 68 years (31 to 90). The mean body mass index was 32.7 kg/m2 (17.3 to 66.4). Results Greater tuberosity stress shielding was noted in 14 shoulders (two TSA and 12 RSA) and was graded as mild in nine, moderate in two, and severe in three. Medial calcar resorption was noted in 23 shoulders (seven TSA and 16 RSA), and was graded as mild in 21 and moderate in two. No humeral components were revised for loosening or considered to be loose radiologically. Nine shoulders underwent reoperation for infection (n = 3), fracture of the humeral tray (n = 2), aseptic glenoid loosening (n = 1), and instability (n = 3). No periprosthetic fractures occurred. Conclusion Implantation of this particular short cementless humeral component at the time of TSA or RSA was associated with a low rate of adverse radiological findings on the humeral side at mid-term follow-up. Our data do not raise any concerns regarding the use of a short stem in TSA or RSA. Cite this article: Bone Joint J 2019;101-B:610–614.
On the Association Between Fluoroquinolones and Neuropathy
Staff, Nathan P. , Dyck, P. James B. , Staff, Nathan P

Mayo Clinic

JAMA Neurology | April 30, 2019 | Volume: 76 | Issue: 7 | Pages: 753

10.1001/jamaneurol.2019.0886 | PMID 31034010 Get It

The Positive Impact of Registered Nurse Sedation Teams
Judd, Marlea A., Warner, Mary E.

Mayo Clinic

Nursing and Health Care | April 30, 2019 | Volume: No volume available | Issue: No issue available | Pages: 21-24

10.33805/2573.3877.132 Get It

Background: Sedation care documentation and patient safety on general care nursing units need improvement. Purpose: To assess the impact of implementation of a registered nurse sedation team model on patient safety and thoroughness of documentation in patients receiving moderate sedation on general care units. Methods: In 2010 a 3-month retrospective chart review determined adverse patient outcomes and incompleteness of documentation for patients receiving sedation on general care units. After implementation of the registered nurse sedation team model for 3 months, patient’s sedation documentation and outcomes were assessed. The registered nurse sedation team model was implemented into practice and further outcome data from implementation through 2017 also were assessed. Results: There was clear improvement in both required documentation during moderate sedation and patient safety (P<0.001). Conclusion: The registered nurse sedation team model in this study improved both completeness of required sedation documentation and patient safety.
Alemtuzumab Induction Versus Conventional Immunosuppression in Heart Transplant Recipients
Gale, Stormi E. , Ravichandran, Bharath , Pham, Si, Ton, Van‐Khue , Pham, Si M. , Reed, Brent N.

Mayo Clinic

Journal of Cardiovascular Pharmacology and Therapeutics | April 30, 2019 | Volume: 24 | Issue: 5 | Pages: 435-441

10.1177/1074248419841635 | PMID 31035777 Get It

The use of alemtuzumab for induction therapy in orthotopic heart transplantation remains controversial, despite its observed benefits in other transplant populations. This study aimed to evaluate whether alemtuzumab conferred a lower risk of rejection while reducing toxicities commonly attributed to standard immunosuppression in orthotopic heart transplantation. We included adult patients who underwent orthotopic heart transplantation and received induction therapy with alemtuzumab (n = 26) or standard immunosuppression (n = 26). The primary end point was freedom from grade ≥2 rejection at 12 months. Baseline characteristics were similar between the groups with the exception of poorer renal function in the alemtuzumab group ( P < .05). The primary end point of freedom from grade ≥2 rejection at 12 months was not different between alemtuzumab and standard therapy (76.9% vs 96.2%, P = .077), likely due to similarities in the rates of antibody-mediated rejection in the 2 groups. However, grade ≥2 acute cellular rejection was considerably lower with alemtuzumab (0% vs 19.2%, P = .02), as was acute cellular rejection of any severity (50% vs 7.7%, P = .004). Deterioration in renal function was significantly greater among patients receiving standard therapy as evidenced by decreases in glomerular filtration rate (−25.6 vs −9.2 mL/min, P = .032). No differences in hematologic or infectious complications were observed. In conclusion, alemtuzumab reduced several important rejection-related outcomes while ameliorating the toxicities associated with standard immunosuppression therapy, making it a promising agent for induction in orthotopic heart transplantation.
Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?
Duma, Narjust , Abdel-Ghani, Azzouqa, Yadav, Siddhartha , Hoversten, Katherine P., Reed, Clay T. , Sitek, Andrea , Enninga, Elizabeth Ann L. , Aguilera, Jesus Vera, Leventakos, Konstantinos , Lou, Yanyan , Kottschade, Lisa A. , Mansfield, Aaron S. , Adjei, Alex A. , Dronca, Roxana , Sitek, Andrea N, Manochakian, Rami , Dronca, Roxana S., Mansfield, Aaron S , Yadav, Siddhartha , Enninga, Elizabeth Ann L , Paludo, Jonas , Dong, Haidong

Mayo Clinic

The Oncologist | April 29, 2019 | Volume: 24 | Issue: 11 | Pages: e1148-e1155

10.1634/theoncologist.2019-0094 | PMID 31036771 Get It

Abstract Background Immune-related adverse events (irAEs) have emerged as a serious clinical issue in the use of immune checkpoint inhibitors (ICIs). Risk factors for irAEs remain controversial. Therefore, we studied sex differences in irAEs in patients treated with anti-programmed cell death protein 1 (PD-1) therapy. Materials and Methods All patients with metastatic melanoma and non-small cell lung cancer (NSCLC) treated with anti-PD-1 therapy at Mayo Clinic Rochester and Florida from 2015 to 2018 were reviewed. Kaplan-Meier method and log-rank test was used for time-to-event analysis. Results In 245 patients with metastatic melanoma, premenopausal women were more likely to experience irAEs (all grades) compared with postmenopausal women and men (67% vs. 60% vs. 46%), primarily because of an increase in endocrinopathies (33% vs. 12% vs. 10%, respectively). In patients with NSCLC (231 patients), women (all ages) were also more likely to develop irAEs of all grades (48% vs. 31%). Women with NSCLC were more likely to develop pneumonitis (11% vs. 4%) and endocrinopathies (14% vs. 5%). No differences in grade ≥3 toxicities were seen across sexes in both cohorts, but women were more likely to receive systemic steroids for the treatment of irAEs compared with men. Better progression-free-survival was observed in women with NSCLC and irAEs (10 months vs. 3.3 months) compared with women without irAEs. Conclusion Women with metastatic melanoma and NSCLC are more likely to experience irAEs compared with men. We also observed differences between sexes in the frequency of certain irAEs. Larger studies are needed to investigate the mechanisms underlying these associations. Implications for Practice The results of this study suggest that women may be at a higher risk for immune-related adverse events (irAEs) compared with men when treated with anti-programmed cell death protein 1 therapy. In addition, women were more likely to develop certain irAEs, including endocrinopathies and pneumonitis. Close follow-up of women undergoing treatment with immune checkpoint inhibitors will allow clinicians to diagnose these treatment-related complications early, potentially reducing their associated morbidity and mortality. In addition, a possible association between irAEs and response to therapy was observed.
Atypical Fungal Rash
Adel, Fadi , Bellamkonda, Venkatesh R. , Adel, Fadi W M, Bellamkonda, Venkatesh, Adel, Fadi W

Mayo Clinic

Clinical Practice and Cases in Emergency Medicine | April 29, 2019 | Volume: 3 | Issue: 2 | Pages: 166-167

10.5811/cpcem.2019.1.41329 | PMID 31061980 Get It

Calmodulin mutations and life-threatening cardiac arrhythmias: insights from the International Calmodulinopathy Registry
Crotti, Lia , Spazzolini, Carla , Tester, David J. , Ghidoni, Alice , Baruteau, Alban‐Elouen , Beckmann, Britt Maria , Behr, Elijah R. , Bennett, Jeffrey S. , Bezzina, Connie R. , Bhuiyan, Zahurul A. , Çeliker, Alpay, Cerrone, Marina , Etheridge, Susan P. , Fatah, Meena , García‐Pavía, Pablo , Hamilton, Robert M. , Al‐Hassnan, Zuhair N. , Horie, Minoru , Jiménez‐Jáimez, Juan , Kanter, Ronald J. , Kaski, Juan Pablo , Kotta, Maria‐Christina , Lahrouchi, Najim , Makita, Naomasa , Norrish, Gabrielle , Odland, Hans Henrik , Ohno, Seiko , Papagiannis, John , Parati, Gianfranco , Sekarski, Nicole , Tveten, Kristian , Vatta, Matteo , Wilde, Arthur A.M. , Wojciak, Julianne, Ackerman, Michael J. , Crotti, Lia , Makita, Naomasa , Horie, Minoru , Behr, Elijah Raphael , Kotta, Maria-Christina , Baruteau, Alban-Elouen , Garcia-Pavia, Pablo , Cerrone, Marina , Hamilton, Robert , Kaski, Juan P , Odland, Hans H , Sekarski, Nicole , Bezzina, Connie R , Spazzolini, Carla , Çeliker, Alpay , Dagradi, Federica , Ferrari, Gaetano Maria De , Al-Ghamdi, Saleh, Ohno, Seiko , Webster, Gregory , George, Alfred L. , Schwartz, Peter J.

Mayo Clinic

European Heart Journal | April 29, 2019 | Volume: 40 | Issue: 35 | Pages: 2964-2975

10.1093/eurheartj/ehz311 | PMID 31170290 Get It

Abstract Aims Calmodulinopathies are rare life-threatening arrhythmia syndromes which affect mostly young individuals and are, caused by mutations in any of the three genes (CALM 1–3) that encode identical calmodulin proteins. We established the International Calmodulinopathy Registry (ICalmR) to understand the natural history, clinical features, and response to therapy of patients with a CALM-mediated arrhythmia syndrome. Methods and results A dedicated Case Report File was created to collect demographic, clinical, and genetic information. ICalmR has enrolled 74 subjects, with a variant in the CALM1 (n = 36), CALM2 (n = 23), or CALM3 (n = 15) genes. Sixty-four (86.5%) were symptomatic and the 10-year cumulative mortality was 27%. The two prevalent phenotypes are long QT syndrome (LQTS; CALM-LQTS, n = 36, 49%) and catecholaminergic polymorphic ventricular tachycardia (CPVT; CALM-CPVT, n = 21, 28%). CALM-LQTS patients have extremely prolonged QTc intervals (594 ± 73 ms), high prevalence (78%) of life-threatening arrhythmias with median age at onset of 1.5 years [interquartile range (IQR) 0.1–5.5 years] and poor response to therapies. Most electrocardiograms (ECGs) show late onset peaked T waves. All CALM-CPVT patients were symptomatic with median age of onset of 6.0 years (IQR 3.0–8.5 years). Basal ECG frequently shows prominent U waves. Other CALM-related phenotypes are idiopathic ventricular fibrillation (IVF, n = 7), sudden unexplained death (SUD, n = 4), overlapping features of CPVT/LQTS (n = 3), and predominant neurological phenotype (n = 1). Cardiac structural abnormalities and neurological features were present in 18 and 13 patients, respectively. Conclusion Calmodulinopathies are largely characterized by adrenergically-induced life-threatening arrhythmias. Available therapies are disquietingly insufficient, especially in CALM-LQTS. Combination therapy with drugs, sympathectomy, and devices should be considered.
Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta‐Blockers in European Americans
Singh, Sonal , Rouby, Nihal El , McDonough, Caitrin W. , Bailey, Kent R. , Boerwinkle, Eric , Chapman, Arlene B. , Gums, John G. , Johnson, Julie A. , Chapman, Arlene B. , Turner, Stephen T. , Gong, Yan , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Clinical and Translational Science | April 29, 2019 | Volume: 12 | Issue: 5 | Pages: 497-504

10.1111/cts.12643 | PMID 31033190 Get It

European Americans (EA) have a better antihypertensive response to β‐blockers when compared with African Americans, albeit with some variability. We undertook a genomewide association study to elucidate the underlying genetic determinants in EA contributing to this variability in blood pressure (BP) response. A discovery genomewide association study of change in BP post–metoprolol treatment was performed in EA participants (n = 201) from the Pharmacogenomic Evaluation of Antihypertensive Responses‐2 (PEAR‐2) study and tested for replication in the atenolol‐treated EA from the PEAR study (n = 233). Rs294610 in the FGD5, which encodes for FYVE, RhoGEF and PH Domain Containing 5, (expression quantitative trait loci for FGD5 in the small intestine) was significantly associated with increased diastolic BP response to β‐blockers in the PEAR‐2 study (P = 3.41 × 10−6, β = −2.70) and replicated (P = 0.01, β = −1.17) in the PEAR study. Post–meta‐analysis of these studies, an additional single nucleotide polymorphism rs45545233 in the SLC4A1, encoding for Solute Carrier Family 4 Member 1, (expression quantitative trait loci for dual specificity phosphatase 3 in the artery tibial) was identified that was significantly associated with a poor response to β‐blockers (P = 3.43 × 10−6, β = 4.57) and was replicated in the atenolol add‐on cohort (P = 0.007, β = 4.97). We identified variants in FGD5 and SLC4A1, which have been previously cited as candidate genes for hypertension, to be associated with a β‐blocker BP response in EA. Further elucidation is warranted of the underlying mechanisms of these variants and genes by which they influence the BP response to β‐blockers.